Login / Signup

The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

Kate C TathamManu Shankar-HariYaseen M Arabi
Published in: Intensive care medicine (2021)
Keyphrases
  • coronavirus disease
  • sars cov
  • phase iii
  • study protocol
  • phase ii
  • clinical trial
  • randomized controlled trial
  • respiratory syndrome coronavirus
  • open label